Alexion (NASDAQ: ALXN)
Alexion is a global biopharmaceutical company focused on rare diseases through innovation, development and commercialisation of therapies. The company was founded in 1992 and has 2,500 employees serving patients in 50 countries around the world.
BREAKTHROUGH THERAPIES
Alexion has delivered therapies to patients suffering from rare diseases. The company has pioneered the complex field of complement biology and delivered solutions to patients with complement-mediated and metabolic disorders.
Alexion developed Soliris® (eculizumab), the world’s first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).
Alexion also has two enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).
The company’s website can be found here.